Opinion|Videos|September 3, 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
- What are some key takeaways regarding the outcomes of treating MDS with oral decitabine-cedazuridine compared with intravenous decitabine, according to the ASCERTAIN data?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD
3
Primary Care Capacity Gaps Threaten Respiratory Prevention
4
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
5